Use of a promoter of T-cell expansion and an inducer of CD40...

Details Use of a promoter of T-cell expansion and an inducer of CD40... Use of a promoter of T-cell expansion and an inducer of CD40...

2007-02-13

2007-02-13

Mertz, Prema (Department: 1646)

Drug, bio-affecting and body treating compositions

Lymphokine

Interleukin

C424S141100, C424S143100, C514S002600, C514S008100, C514S012200

Reexamination Certificate

active

10226959

ABSTRACT:
The invention provides a method of treating or preventing a pathologic state in a mammal. The method comprises administering to the mammal a promoter of T-cell expansion and an inducer of CD40 stimulation, wherein CD40 is stimulated on cells of the immune system. The promoter of T-cell expansion and inducer of CD40 stimulation are administered in synergistically effective amounts to treat or prevent the pathologic state in the mammal. The invention also provides a method of assessing the effectiveness of treatment of a pathologic state in a mammal, wherein the mammal has been administered a promoter of T-cell expansion and an inducer of CD40 stimulation, wherein CD40 is stimulated on cells of the immune system. The method comprises measuring the level of at least one antibody in a test sample obtained from the mammal, which at least one antibody is specific for an antigen that is known to be associated with the pathologic state, and wherein the level of the at least one antibody is indicative of the effectiveness of treatment of the pathologic state in the mammal.

REFERENCES:
patent: 5843648 (1998-12-01), Robbins et al.
patent: 6045788 (2000-04-01), Smith
patent: 6106823 (2000-08-01), Vieira et al.
patent: WO 99/32138 (1999-07-01), None
French et al (May 1999) Nature Medicine, vol. 5, No. 5, pp. 548-553.
Chum Tharapai et al (1997) Methods in Enzymology, vol. 288, pp. 15-27.
Beers & Berkow Editors, The Merck Manual, 17thedition, pp. 165-177, pp. 986-995, (1999).
French et al. (May 1999) Nature Medicine, vol. 5, No. 5, pp. 548-553.
Chuntharapai et al (1997) Method on Enzymology, vol. 288, pp. 15-27.
Beers & Berkow, The Merck Manual, 17thedition, pp. 986-995, (1999).
Mendiratta et al.,Human Gene Therapy, 11, 1851-1862 (Sep. 1, 2000).
Von Leoprechting et al.,Cancer Research, 59, 1287-1294 (Mar. 15, 1999).
Ziebold et al.,Arch. Immunol. Ther. Exp., 48, 225-233 (2000).
Aguirre et al., “Role of tumor necrosis factor and gamma interferon in acquired resistance toCryptococcus neoformansin the central nervous system of mice,”Infect. Immun., 63, 1725-1731 (1995).
Armitage et al., “CD40L: a multi-functional ligand,”Semin. Immunol., 5, 401-412 (1993).
Bag, “Fungal pneumonias in transplant recipients,”Curr. Opin. Pulm. Med., 9, 193-198 (2003).
Banchereau et al., “The CD40 antigen and its ligand,”Annu. Rev. Immunol., 12, 881-922 (1994).
Barchiesi et al., “Posaconazole and amphotericin B combination therapy againstCryptococcus neoformansinfection,”Antimicrob. Agents Chemother., 48, 3312-3316 (2004).
Billiau et al., “Immunomodulatory properties of interferon-gamma. An update,”Ann. N.Y. Acad. Sci., 856, 22-32 (1998).
Bogdan, “The function of type I interferons in antimicrobial immunity,”Curr. Opin. Immunol., 12, 419-424 (2000).
Caux et al., “Activation of human dendritic cells through CD40 cross-linking,”J. Exp. Med., 180, 1263-1272 (1994).
Charlier et al., “Capsule structure changes associated withCryptococcus neoformanscrossing of the blood-brain barrier,”Am. J. Pathol., 166, 421-432 (2005).
Chen et al., “The gamma interferon receptor is required for the protective pulmonary inflammatory response toCryptococcus neoformans,” Infect. Immun., 73, 1788-1796 (2005).
Chiller et al., “Effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on polymorphonuclear neutrophils, monocytes or monocyte-derived macrophages combined with voriconazole againstCryptococcus neoformans,” Med. Mycol., 40, 21-26 (2002).
Dromer et al., “Protection of mice against experimentalcryptococcosisby anti-Cryptococcus neoformansmonoclonal antibody,”Infect. Immun., 55, 749-752 (1987).
Dullforce et al., “Enhancement of T cell-independent immune responses in vivo by CD40 antibodies,”Nat. Med., 4, 88-91 (1998).
Grewal et al., “CD40 and CD154 in cell-mediated immunity,”Annu. Rev. Immunol., 16, 111-135 (1998).
Herring et al., “Induction of interleukin-12 and gamma interferon requires tumor necrosis factor alpha for protective T1-cell-mediated immunity to pulmonaryCryptococcus neoformansinfection,”Infect. Immun., 70, 2959-2964 (2002).
Huffnagle, “Role of cytokines in T cell immunity to a pulmonaryCryptococcus neoformansinfection,”Biol. Signals, 5, 215-222 (1996).
Huffnagle et al., “Afferent phase production of TNF-alpha is required for the development of protective T cell immunity toCryptococcus neoformans,” J. Immunol., 157, 4529-4536 (1996).
Kawakami et al., “NK cells eliminateCryptococcus neoformansby potentiating the fungicidal activity of macrophages rather than by directly killing them upon stimulation with IL-12 and IL-18,”Microbiol. Immunol., 44, 1043-1050 (2000).
Koguchi et al., “Cryptococcalinfection and Th1-Th2 cytokine balance,”Int. Rev. Immunol., 21, 423-438 (2002).
Kozel et al., Bivalency is required for anticapsular monoclonal antibodies to optimally suppress activation of the alternative complement pathway by theCryptococcus neoformanscapsule,Infect. Immun., 66, 1547-1553 (1998).
Kozel et al., “mAbs toBacilus anthraciscapsular antigen for immunoprotection in anthrax and detection of antigenemia,”Proc. Natl. Acad. Sci. U.S.A, 101, 5042-5047 (2004).
Kumaratilake et al., “The role of T lymphocytes in immunity toPlasmodium falciparum. Enhancement of neutrophil-mediated parasite killing by lymphotoxin and IFN-gamma: comparisons with tumor necrosis factor effects,”J. Immunol., 146, 762-767 (1991).
Le Page et al., “Interferon activation and innate immunity,”Rev. Immunogenet., 2, 374-386 (2000).
Leinonen et al., “Class-specific antibody response to group BNeisseria meningitidiscapsular polysaccharide: use of polylysine precoating in an enzyme-linked immunosorbent assay,”Infect. Immun., 38, 1203-1207 (1982).
Levy et al., “Clinical spectrum of X-linked hyper-IgM syndrome,”J. Pediatr., 131, 47-54 (1997).
Lutz et al., “Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemiccryptococcosis,” J. Antimicrob. Chemother., 46, 437-442 (2000).
Ma et al., “CD8 T cell-mediated killing ofCryptococcus neoformansrequires granulysin and is dependent on CD4 T cells and IL-15,”J. Immunol., 169, 5787-5795 (2002).
Mambula et al., “Human neutrophil-mediated nonoxidative antifungal activity againstCryptococcus neoformans,” Infect. Immun., 68, 6257-6264 (2000).
Mukherjee et al., “Therapeutic efficacy of monoclonal antibodies toCryptococcus neoformansglucuronoxylomannan alone and in combination with amphotericin,”B. Antimicrob. Agents Chemother., 38, 580-587 (1994).
Murphy et al., “Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses,”J. Immunol., 170, 2727-2733 (2003).
Pietrella et al., “Disruption of CD40/CD40L interaction influences the course ofCryptococcus neoformansinfection,”FEMS Immunol. Med. Microbiol., 40, 63-70 (2004).
Ross et al., “Cryptococcal meningitisandsarcoidosis,” Scand. J. Infect. Dis., 34, 937-939 (2002).
Sabeti et al., “CD40L association with protection from severe malaria,”Genes Immun., 3, 286-291 (2002).
Shoham et al., “The immune response to fungal infections,”Br. J. Haematol., 129, 569-582 (2005).
Siddiqui et al., “IFN-gamma at the site of infection determines rate of clearance of infection incryptococcal meningitis,” J. Immunol., 174, 1746-1750 (2005).
Sundstrom et al., “The glucuronoxylomannan ofCryptococcus neoformansserotype A is a type 2 T-cell-independent antigen,”Infect. Immun., 60, 4080-4087 (1992).
Uicker et al., “Cytokine and chemokine expression in the central nervous system associated with protective cell-mediated immunity againstCryptococcus neoformans

Affiliated with

Also associated with

Rating

Use of a promoter of T-cell expansion and an inducer of CD40... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of a promoter of T-cell expansion and an inducer of CD40..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of a promoter of T-cell expansion and an inducer of CD40... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3860348